CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性

doi:10.3760/cma.j.cn371439-20231203-00041

摘要/Abstract

摘要：

目的回顾性分析CD30单抗（维布妥昔单抗）联合程序性死亡受体1（PD-1）抑制剂（替雷利珠单抗）治疗复发难治性霍奇金淋巴瘤（R/R HL）的疗效和安全性。方法回顾性分析2022年6月至2023年6月华中科技大学协和深圳医院血液内科收治的12例接受维布妥昔单抗+替雷利珠单抗治疗的R/R HL患者的病例资料。根据2014年Lugano修订版淋巴瘤疗效评价标准评估疗效。使用Kaplan-Meier法进行生存分析。采用美国国立癌症研究所通用不良反应术语标准5.0版对不良反应进行评价和分级。结果 12例R/R HL患者中10例客观缓解，其中5例完全缓解。中位随访时长9.5个月（范围：6~15个月），中位无进展生存期为9.5个月，中位总生存期未达到。维布妥昔单抗+替雷利珠单抗治疗的主要不良反应是贫血（5例）、周围神经病（4例）、疲乏（4例）、转氨酶升高（3例）、中性粒细胞减少（2例）、输液反应（2例）、免疫相关性皮疹（2例）、脱发（2例），基本为1~2级，其中4级中性粒细胞减少1例，未观察到3级不良反应。结论维布妥昔单抗+替雷利珠单抗治疗R/R HL患者的疗效良好，不良反应可控。

关键词: 霍奇金病, 维布妥昔单抗, Ki-1抗原, 免疫检查点抑制剂, 替雷利珠单抗

钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.

图/表 2

表1

表2

参考文献 27

[1]	Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress[J]. CA Cancer J Clin, 2018, 68(2): 116-132. DOI: 10.3322/caac.21438.
[2]	中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(7): 707-735. DOI: 10.3760/cma.j.cn112152-20210516-00382.
[3]	Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis[J]. Am J Hematol, 2017, 92(9): 879-884. DOI: 10.1002/ajh.24792. pmid: 28512788
[4]	Scott LJ. Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma[J]. Drugs, 2017, 77(4): 435-445. DOI: 10.1007/s40265-017-0705-5. pmid: 28190142
[5]	Agarwal P, Bertozzi CR. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development[J]. Bioconjug Chem, 2015, 26(2): 176-192. DOI: 10.1021/bc5004982.
[6]	Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase Ⅱ CheckMate 205 trial[J]. J Clin Oncol, 2018, 36(14): 1428-1439. DOI: 10.1200/JCO.2017.76.0793.
[7]	Song YQ, Wu JQ, Chen XC, et al. A single-arm, multicenter, phase Ⅱ study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma[J]. Clin Cancer Res, 2019, 25(24): 7363-7369. DOI: 10.1158/1078-0432.CCR-19-1680.
[8]	中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会, 中国霍奇金淋巴瘤工作组. 中国霍奇金淋巴瘤的诊断与治疗指南(2022年版)[J]. 中华血液学杂志, 2022, 43(9): 705-715. DOI: 10.3760/cma.j.issn.0253-2727.2022.09.001.
[9]	Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-3068. DOI: 10.1200/JCO.2013.54.8800. pmid: 25113753
[10]	Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92. DOI: 10.1016/j.ad.2019.05.009.
[11]	Castagna L, Santoro A, Carlo-Stella C. Salvage therapy for Hodgkin's lymphoma: a review of current regimens and outcomes[J]. J Blood Med, 2020, 11: 389-403. DOI: 10.2147/JBM.S250581. pmid: 33149713
[12]	Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase Ⅱ study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma[J]. J Clin Oncol, 2012, 30(18): 2183-2189. DOI: 10.1200/JCO.2011.38.0410. pmid: 22454421
[13]	Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma[J]. Blood, 2016, 128(12): 1562-1566. DOI: 10.1182/blood-2016-02-699850. pmid: 27432875
[14]	Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma[J]. Blood, 2015, 125(8): 1236-1243. DOI: 10.1182/blood-2014-08-595801. pmid: 25533035
[15]	Walewski J, Hellmann A, Siritanaratkul N, et al. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy[J]. Br J Haematol, 2018, 183(3): 400-410. DOI: 10.1111/bjh.15539.
[16]	Plattel WJ, Bergamasco A, Trinchese F, et al. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis[J]. Leuk Lymphoma, 2021, 62(14): 3320-3332. DOI: 10.1080/10428194.2021.1957865.
[17]	LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma[J]. Blood, 2018, 132(1): 40-48. DOI: 10.1182/blood-2017-11-815183. pmid: 29703778
[18]	Broccoli A, Argnani L, Botto B, et al. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi[J]. Blood Cancer J, 2019, 9(12): 100. DOI: 10.1038/s41408-019-0265-x. pmid: 31827067
[19]	Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage Ⅲ or Ⅳ classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial[J]. Lancet Haematol, 2021, 8(6): e410-e421. DOI: 10.1016/S2352-3026(21)00102-2. pmid: 34048680
[20]	Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)[J]. Ann Oncol, 2019, 30(4): 612-620. DOI: 10.1093/annonc/mdz009. pmid: 31987279
[21]	Hagenbeek A, Mooij H, Zijlstra J, et al. Phase Ⅰ dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the HOVON/LLPC Transplant BRaVE study[J]. Haematologica, 2019, 104(4): e151-e153. DOI: 10.3324/haematol.2018.196899.
[22]	Cole PD, McCarten KM, Pei QL, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial[J]. Lancet Oncol, 2018, 19(9): 1229-1238. DOI: 10.1016/S1470-2045(18)30426-1. pmid: 30122620
[23]	Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older[J]. Blood, 2015, 126(26): 2798-2804. DOI: 10.1182/blood-2015-06-644336. pmid: 26377597
[24]	Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL[J]. Blood, 2017, 130(26): 2829-2837. DOI: 10.1182/blood-2017-06-787200. pmid: 29038340
[25]	Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma[J]. Blood, 2018, 131(11): 1183-1194. DOI: 10.1182/blood-2017-10-811224. pmid: 29229594
[26]	Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results[J]. Blood, 2021, 138(6): 427-438. DOI: 10.1182/blood.2020009178. pmid: 33827139
[27]	Herrera AF, Chen L, Nieto Y, et al. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial[J]. Lancet Haematol, 2023, 10(1): e14-e23. DOI: 10.1016/S2352-3026(22)00318-0.

病例	性别	年龄（岁）	病理类型	Ann Arbor 分期	B症状	结外侵犯	IPI评分（分）	ECOG评分（分）	前期治疗线数	前期使用 PD-1 抑制剂	曾行 auto-HSCT	从确诊到使用BV 时间（月）	疗效评估
1	女	49	结节硬化型	Ⅱ期	无	无	1	0	3	是	否	36	CR
2	男	68	混合细胞型	ⅢE期	有	有	3	1	6	是	否	100	PD
3	男	52	结节硬化型	ⅢE期	有	有	4	2	5	是	否	89	CR
4	女	47	结节硬化型	Ⅳ期	有	有	3	0	5	是	否	118	CR
5	男	15	结节硬化型	Ⅳ期	有	有	3	0	6	是	是	57	CR
6	女	31	结节硬化型	Ⅳ期	有	有	3	2	6	是	是（2次）	92	PR
7	男	75	混合细胞型	Ⅳ期	有	有	5	2	2	是	否	18	CR
8	女	29	结节硬化型	ⅢE期	无	有	2	1	4	是	是	82	PR
9	男	52	结节硬化型	Ⅲ期	有	无	2	1	3	是	是	38	PR
10	男	42	结节硬化型	Ⅱ期	无	无	1	0	2	是	否	30	SD
11	女	18	结节硬化型	Ⅲ期	无	无	2	0	4	是	否	19	PR
12	男	25	富于淋巴细胞型	Ⅲ期	无	有	1	1	2	是	否	76	PR